COO

Business profile & competitive position

The Cooper Companies, Inc. is a global medical device company headquartered in San Ramon, California, classified in the Healthcare sector and the Medical - Instruments & Supplies industry. It operates two distinct business units: CooperVision, which develops, manufactures and markets single-use, two-week and monthly contact lenses plus specialty eyecare products such as silicone hydrogel lenses, myopia management lenses, orthokeratology and scleral lenses; and CooperSurgical, which supplies more than 600 products and services focused on fertility and women’s health, including gynecology, obstetrics, contraception, labor and delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services.

The company’s current margin profile is modest in absolute terms. The trailing net margin is 5.6% and return on equity is 2.8%. Those figures do not point to a deep, capital-light competitive moat on profitability alone; they suggest a business reinvesting heavily, carrying meaningful acquisition or R&D costs, or operating in segments where pricing pressure and reimbursement dynamics compress reported earnings. At the same time, the market capitalization of $14.7 billion implies investors are paying for future growth rather than current returns. The clearer strategic differentiator is product breadth and regulatory positioning. MiSight 1 day, for instance, is the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to slow the progression of and correct myopia in age-appropriate children. That kind of first-mover regulatory footprint, combined with a roughly 500-person R&D organization and distribution into over 130 countries, frames Cooper as a scale player investing to convert leadership in niche eyecare and women’s health categories into durable market share rather than harvesting short-term margin.

Financial posture

Cooper’s valuation currently sits at a trailing P/E of 63.7 on a market cap of $14.7 billion, well above the multiples typical of Healthcare operators with mature, cash-cow profiles. That premium is set against a net margin of 5.6% and an ROE of 2.8%, both of which are low relative to the valuation. The implied message is that market participants expect earnings to accelerate from today’s base, whether through operating leverage in CooperVision, contribution from CooperSurgical expansion, or both.

The stock also carries a beta of 0.82, meaning it has historically been somewhat less volatile than the broad equity market. That is consistent with a defensive Healthcare name, but the valuation itself is not defensive; it reflects growth expectations. The data provided do not include a specific debt figure, so the leverage picture cannot be quantified here. From the available metrics, the central financial tension is between a low-margin, low-ROE present and a market-implied expectation of substantially higher future profits.

Strategic priorities & outlook

In its most recent SEC 10-K filing, the company outlined near-term priorities that line up closely with the valuation premium described above. For CooperVision, management is focused on driving greater worldwide market penetration of recently introduced products and expanding the company’s presence in both existing and emerging markets. That expansion is supported by increased investment in distribution and packaging capabilities to keep service levels aligned with growth.

A second CooperVision priority is market development around myopia management. The company is investing to educate eye care practitioners, patients and families, effectively trying to expand the total addressable market rather than simply taking share within the current pool of contact lens wearers. On the CooperSurgical side, the company expects to continue investing in the business, including through strategic transactions, to build out its integrated solutions model in fertility and women’s health. The combination points to a multi-year playbook: grow the installed base and awareness in CooperVision while using M&A and integrated product bundles to deepen CooperSurgical’s reach.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company with global revenue, Cooper faces exposures common to the industry rather than unique to this ticker. Regulatory risk is central: contact lenses and fertility devices must win and maintain approvals from the FDA and equivalent agencies abroad, and any delay in clinical data or labeling changes can influence revenue timelines. Currency translation is a steady factor, since products are sold in over 130 countries; a stronger U.S. dollar would compress reported overseas revenue and vice versa.

Supply-chain sensitivity is also relevant. Contact lens production depends on specialized polymers and precision manufacturing, while surgical and fertility products can involve biologic materials and cold-chain logistics. Trade policy, tariffs or shipping disruptions can therefore affect input costs and margins. Reimbursement and policy shifts in healthcare spending, including coverage decisions for fertility treatments or myopia management, can influence demand elasticity. Demographic tailwinds such as rising myopia prevalence and delayed childbearing support long-term categories, but those trends also draw scrutiny on pricing and access from regulators and payers.

Recent developments

The recent headline feed for the COO ticker window, dated between August 5 and August 12, 2026, returned the following items: On August 12, 2026, Gurufocus reported that Minesto adapted its organization to strengthen customer service offering. On August 11, 2026, TechCrunch reported that Brad Lightcap, OpenAI’s longtime COO, was leaving to “start something new.” On August 6, 2026, Gurufocus highlighted Motorola Solutions’ Q2 2026 earnings call, which discussed record sales and raised guidance. On August 5, 2026, Gurufocus covered Assurant’s Q2 2026 earnings call, noting record results driven by connected living and strategic wins.

None of these headlines refer directly to The Cooper Companies, but they illustrate the kind of cross-ticker noise that can appear in feeds around a ticker symbol; traders should rely on company-specific releases rather than unrelated ticker-mixed items when evaluating COO.

Earnings behavior & post-earnings drift

Cooper has delivered reliable beats in the recent past. Over the last eight reported quarters, the company beat estimates in 8 of 8 cases, producing a 100% beat rate with an average earnings surprise of 4.6%. Despite that consistency, the average five-trading-day price move after earnings across those quarters was -0.91%, classified as a downward post-earnings drift. That disconnect is important: beating estimates does not automatically translate into positive price performance if the unofficial consensus was higher, guidance disappointed, or valuation already embedded the beat.

The last four quarters show the pattern clearly. On June 4, 2026, Cooper reported $1.21 versus an estimate of $1.10, a 10% surprise, and the stock rose 8.58% the next day and 8.85% over the following five days. On March 5, 2026, EPS came in at $1.10 versus $1.03 (a 6.8% beat), yet the stock fell 4.55% the next session and 10.82% over five days. On December 4, 2025, Cooper earned $1.15 against $1.11 (a 3.6% beat), driving a 5.67% next-day gain and a 6.59% five-day gain. Then on August 27, 2025, the company reported $1.10 versus $1.07 (a 2.8% beat), only to see the stock plunge 12.86% the next day and 8.24% over five days.

The next scheduled release is September 9, 2026, after the market close, with consensus EPS at $1.12. At the current snapshot, the stock is trading near $75.22, with an RSI of 58.3 and a 50-day EMA of $71.59. The historical beat rate suggests the company often clears the published estimate, but the mixed post-earnings price reactions underline that the post-event move depends on what the market’s real expectation had priced in and what management says about the quarters ahead.

For a deeper look at how institutional analysts are interpreting Cooper’s balance sheet, strategic execution and earnings setup heading into the September 9 report, review the full institutional verdict on the ticker page.